IPSEN (OTCMKTS:IPSEY) Sees Strong Trading Volume – Here’s Why

IPSEN (OTCMKTS:IPSEY) shares saw an uptick in trading volume on Tuesday. 3,850 shares were traded during mid-day trading, an increase of 95% from the average daily volume of 1,975 shares. The stock last traded at $42.35 and had previously closed at $43.56.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IPSEY. HC Wainwright restated a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Barclays raised IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, IPSEN presently has a consensus rating of “Hold”.

IPSEN Trading Down 1.9%

The stock’s fifty day moving average is $44.24 and its 200-day moving average is $45.06.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.